UNSPSC 51143500: Combination antiparkinson agents

This classification denotes combination drugs used in the treatment of a progressive, degenerative neurologic disease characterized by a tremor that is maximal at rest, retropulsion, rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression, a disorder called Parkinson Disease, hence the term ANTIPARKINSON AGENTS. Typical combination Antiparkinson agent constituents are carbidopa and levodopa.

UNSPSC 51143500 Combination antiparkinson agents is a Class code, but the recent state and local opportunities tagged under it do not reflect the code's nominal pharmaceutical scope. Instead, the opportunities center on naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — a category mismatch that signals the code may be misapplied or overly broad in state and local systems. Where the code is used, state and local governments are sourcing pharmaceutical products through competitive bidding processes, cooperative purchasing vehicles, and request-for-information mechanisms designed to establish supply relationships with manufacturers and authorized wholesalers. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that serve participating government agencies and local jurisdictions.

Recent activity spans Florida, Texas, and Minnesota-led multi-state purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems (1,900 units and 800 systems annually, respectively) with quarterly delivery to its Community Health Building, due by July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, including Oregon; vendors were required to submit proposals by March 26, 2026, with contract awards effective July 1, 2026. MMCAP's structure mandates use of three authorized wholesalers and requires vendors to maintain specific insurance coverage, comply with cGMP and Drug Supply Chain Security Act standards, and accept a 3 percent administrative fee on contract purchases.